All Articles

With staggering revenue growth, key partnerships, and a TSX uplisting, this food-tech innovator is disrupting the global food supply chain.

ProMIS Neurosciences' bet on plasma pTau could make Alzheimer's trials faster and cheaper, giving its unique drug PMN310 a critical edge.

Post's new $1.3B bond deal extends its debt maturity but at a higher cost. We analyze the market's mixed reaction and what it means for future growth.

With $4.25M in new financing, Pulse Oil is betting big on EOR to revive a mature oilfield. Early data shows a 20% production jump.

Medicus Pharma consolidates its C-suite, naming a dual President/CFO to steer its high-stakes push in oncology, urology, and next-gen vaccines.

TPVG just locked in cheaper, long-term capital. We analyze why this move signals deep confidence in the future of AI and software innovation.

Endeavour Silver's massive convertible note offering is a dual play: shedding costly debt while fueling its giant Pitarrilla silver project in Mexico.

A wealth manager's regulatory filing reveals its strategic play in the Empiric Student Property takeover, offering a rare look at M&A endgame tactics.

With revenue soaring and losses cut, Hypercharge's real story is a strategic shift to higher-margin services and carbon credits. Here's why it matters.

A Houston biotech is targeting a devastating cancer complication with a novel radiotherapy. Can REYOBIQ™ change the grim prognosis for leptomeningeal metastases?

A permit delay at a historic silver mine in Peru tests Carlton Precious, highlighting the clash between rich resources and tough environmental rules.

The FDA accelerates a novel immunotherapy for acute myeloid leukemia. Its unique ability to target all FLT3 forms could change the treatment paradigm.

A new alliance aims to use quantum computing to slash the cost and time of creating advanced therapies. But how far are we from qubits to actual cures?

Bicara Therapeutics' latest data for its dual-action antibody shows impressive consistency, de-risking its pivotal trial for a tough head and neck cancer.

A tiny 0.12% stake disclosure seems trivial, but it offers a masterclass in reading M&A signals—a vital skill for investors in any sector.

After past stumbles, Merck unveils two new Alzheimer's candidates targeting different pathways, a high-stakes bet signaling a major strategic shift.

EnviroGold Global is deploying mobile pilot plants to unlock trillions in mine tailings. Is this strategic pivot the key to dominating the green metals race?

In the shadow of giants, a junior miner uses advanced geophysics to de-risk its hunt for a major discovery in the prolific Vicuña District.

How one skincare brand's new SPF, blending biotech and strict safety standards, reveals a powerful business strategy for winning in today's market.

A therapeutic footwear expert is stepping into the rugged $42B outdoor market. Can FitVille's focus on comfort and accessibility disrupt established giants?